ZNF417

Across TCGA pan-cancer cohorts, ZNF417 RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of ZNF417’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where ZNF417 RNA is repressed in tumor relative to normal tissue. In most cancer types ZNF417 is over-expressed in tumor, although a few such as THCA and KICH show the opposite, repressed pattern.

THCA, LIHC, and CHOL are the cancer types where ZNF417 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ZNF417 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	All	II,III,IV	−0.607	<.001	8	view →
LIHC	Female	All	+0.454	<.001	6	view →
CHOL	All	All	+1.131	<.001	5	view →
HNSC	All	All	+0.298	.003	5	view →
STAD	All	II,III,IV	+0.530	.007	3	view →
BLCA	All	All	+0.354	.038	2	view →
KICH	All	All	−0.371	.044	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

ZNF417–THCA

Open the THCA breakdown →